Minimal residual disease in multiple myeloma: past, present, and future
Simple Summary The assessment of responses is critical in patients diagnosed with multiple
myeloma. Nowadays, one of the most informative parameters to discriminate responses to …
myeloma. Nowadays, one of the most informative parameters to discriminate responses to …
Experts' consensus on the definition and management of high risk multiple myeloma
C Marcon, V Simeon, P Deias, G Facchin… - Frontiers in …, 2023 - frontiersin.org
High risk multiple myeloma (HRMM) at diagnosis is currently recognized according to the
Revised International Staging System (R-ISS) which was set up in 2015. Since then, new …
Revised International Staging System (R-ISS) which was set up in 2015. Since then, new …
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
Background For patients with newly diagnosed multiple myeloma, reaching minimal residual
disease (MRD) negativity after treatment is associated with improved outcomes; however …
disease (MRD) negativity after treatment is associated with improved outcomes; however …
Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high-risk newly diagnosed multiple myeloma
LB Leypoldt, D Tichy, B Besemer, M Hänel… - Journal of Clinical …, 2024 - ascopubs.org
PURPOSE The GMMG-CONCEPT trial investigated isatuximab, carfilzomib, lenalidomide,
and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) …
and dexamethasone (Isa-KRd) in transplant-eligible (TE) and transplant-noneligible (TNE) …
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus
lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed …
lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed …
More than 2% of circulating tumor plasma cells defines plasma cell leukemia–like multiple myeloma
T Jelinek, R Bezdekova, D Zihala… - Journal of clinical …, 2023 - ascopubs.org
PURPOSE Primary plasma cell leukemia (PCL) is the most aggressive monoclonal
gammopathy. It was formerly characterized by≥ 20% circulating plasma cells (CTCs) until …
gammopathy. It was formerly characterized by≥ 20% circulating plasma cells (CTCs) until …
Genomic classification and individualized prognosis in multiple myeloma
PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are
heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS …
heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS …
Prognostic impact of translocation t (14; 16) in multiple myeloma according to the presence of additional genetic lesions
A Schavgoulidze, A Perrot, T Cazaubiel, X Leleu… - Blood Cancer …, 2023 - nature.com
Patients with multiple myeloma (MM) have experienced a markedly improved survival over
the past 25 years, thanks in part to the availability of new drugs [1]. However, a subgroup of …
the past 25 years, thanks in part to the availability of new drugs [1]. However, a subgroup of …
Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed/refractory …
PURPOSE Although chimeric antigen receptor T therapy (CAR-T) cells are an established
therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models …
therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models …
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del (1p32) remains a strong prognostic factor
Cytogenetic abnormalities (CAs) are known to be the preponderant prognostic factor in
multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs …
multiple myeloma. Our team has recently developed a prognostic score based on 6 CAs …